Scientific Significance of Clinically Insignificant FcγRIIIa-V158F Polymorphism

Guillaume Cartron (1, 2) , Roch Houot (3, 4) , Holbrook E Kohrt (5)

1 CHU Montpellier
2 DIMNP - Dynamique des interactions membranaires normales et pathologiques
3 MiCa - Microenvironnement et cancer
4 Service d'hématologie clinique
5 Stanford University

Kenkre and colleagues report the absence of correlation between FcγRIIIa-V158F polymorphism and rituximab response in follicular lymphoma patients, a result which is in contrast with prior studies. This discrepancy recalls that many other factors (from the host and from the tumor) may influence the efficacy of rituximab in vivo. Clin Cancer Res; 22(4); 787–9. ©2015 AACR. See related article by Kenkre et al., p. 821

Domains: Life Sciences [q-bio]

Guillaume Cartron, Roch Houot, Holbrook E Kohrt. Scientific Significance of Clinically Insignificant FcγRIIIa-V158F Polymorphism. Clinical Cancer Research, 2016, 22 (4), pp.787--789. ⟨10.1158/1078-0432.CCR-15-2777⟩. ⟨hal-01299291⟩